Development and Validation of CDX Models to Advance Targeted Radioligand Therapy

An integrated in vitro, ex vivo, and xenograft platform enabling robust evaluation of target expression, pharmacology, and efficacy across oncology indications

Targeted therapeutics such as radioligand therapy (RLT) are transforming precision oncology by enabling selective tumor targeting while minimizing damage to healthy tissue. However, successful development depends on access to robust, well-characterized preclinical models capable of reliably evaluating target expression, pharmacology, and therapeutic response.

In this work, we present the development and validation of an integrated platform combining in vitro, ex vivo, and cell line–derived xenograft (CDX) models across multiple tumor indications. This initiative focuses on curating high-priority targets, optimizing cell line selection, and establishing reproducible xenograft growth conditions, supported by comprehensive validation of target expression using flow cytometry, imaging, and histological analysis. Together with a suite of functional and mechanistic assays, this platform provides deep insight into target engagement, receptor occupancy, and therapeutic activity—delivering scientifically rigorous, sponsor-ready models to support.

What You Will Learn

• How integrated in vitro, ex vivo, and CDX models enable more reliable evaluation of targeted oncology therapeutics
• Approaches for validating target expression and relevance across cell lines and xenograft tumors
• Methods for assessing radioligand pharmacology, including binding, internalization, and competitive affinity
• Insights into mechanistic assays evaluating DNA damage, cell-cycle effects, and apoptosis
• How a scalable, validated CDX model portfolio supports translational research and de-risks drug development across RLT, ADC, and small-molecule programs

Learn more about Perceptive Discovery’s preclinical oncology services here.